Key result
Fasting reactive dicarbonyls show no independent association with arterial stiffness.
Why the study?
Increased concentrations of reactive dicarbonyl compounds may cause arterial stiffening, but their association with measures of arterial stiffness in a population-based setting required investigation.
Are fasting plasma concentrations of reactive dicarbonyls independently associated with arterial stiffness in a population-based cohort?
Cross-Sectional (n=2,275)
Are fasting plasma concentrations of reactive dicarbonyls independently associated with arterial stiffness in a population-based cohort?
Fasting plasma concentrations of reactive dicarbonyls (MGO, GO, 3-DG) are not independently associated with arterial stiffness after adjusting for cardiovascular risk factors.
No independent association after adjustment; leaves open longitudinal or interventional roles in arterial stiffness.
BACKGROUND: Arterial stiffness is a strong predictor of cardiovascular diseases and all-cause mortality. Increased concentrations of highly reactive dicarbonyl compounds-methylglyoxal (MGO), glyoxal (GO), and/or 3-deoxyglucosone (3-DG)-may cause arterial stiffening via formation of advanced glycation end products, triggering maladaptive responses in vascular tissue, e.g., elastin degradation and collagen cross-linking. Therefore, we investigated in the population-based Maastricht study whether plasma MGO, GO, and 3-DG concentrations were cross-sectionally associated with carotid-to-femoral pulse wave velocity (cfPWV) and local carotid stiffness measures: pulse wave velocity (cPWV), and Young's elastic modulus (cYEM) using standardized main variables. METHODS: Fasting dicarbonyl concentrations were determined by ultra-performance liquid chromatography tandem mass spectrometry in EDTA plasma collected from 2,275 participants (age 60 ± 8 years, mean ± SD; 49% women, 605 (27%) with type 2 diabetes mellitus) of the Maastricht Study, an observational, population-based cohort study. Cross-sectional associations were assessed using multivariable linear regression analysis adjusting for age, sex, mean arterial pressure (MAP), heart rate, lifestyle factors, and medication. Since arterial stiffness measures are intrinsically pressure dependent, we additionally assessed the associations with pressure-corrected counterparts, instead of statistically correcting for MAP. RESULTS: Fasting dicarbonyl concentrations were associated with arterial stiffness measures (greater cfPWV, cPWV, and cYEM) in most crude models, but not in adjusted models. The use of pressure-corrected metrics did not materially change the association of interest. CONCLUSIONS: Fasting plasma concentrations of either MGO, GO, or 3-DG are not independently associated with arterial stiffness in this cross-sectional analysis.
No takes yet. Share an insight, caveat, or question.
Bruggen et al. (2025) conducted a cross-sectional in Arterial stiffness (n=2,275). Plasma reactive dicarbonyls (MGO, GO, 3-DG) was evaluated on Carotid-to-femoral pulse wave velocity (cfPWV) and local carotid stiffness measures (cPWV, cYEM). Fasting plasma concentrations of reactive dicarbonyls (MGO, GO, and 3-DG) were not independently associated with arterial stiffness measures in adjusted cross-sectional models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: